These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 1343639)
21. [Enhancement of the effect of captopril in the 1st 48 hours of treating refractory heart failure. A comparison with intravenous trinitrine]. Le Pailleur C; Baubion N; Metzger JP; Heulin A; Vacheron A; Di Matteo J Arch Mal Coeur Vaiss; 1984 Jun; 77(6):700-6. PubMed ID: 6431936 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. Chu KM; Shieh SM; Hu OY Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260 [TBL] [Abstract][Full Text] [Related]
24. [Neurohumoral and hemodynamic effects in combination therapy of enoximone and dopamine]. Mitrovic V; Neuzner J; Opper H; Thormann J; Schlepper M Z Kardiol; 1994; 83 Suppl 2():37-48. PubMed ID: 8091823 [TBL] [Abstract][Full Text] [Related]
25. [Hemodynamics after sublingual administration of captopril in severe heart failure. A pilot study]. Haude M; Steffen W; Erbel R; Tschollar W; Belz GG; Meyer J Dtsch Med Wochenschr; 1989 Jul; 114(28-29):1095-100. PubMed ID: 2663409 [TBL] [Abstract][Full Text] [Related]
26. Acute effects of intravenous UD-CG 115 BS (pimobendan) on the cardiovascular system and left ventricular pump function. Permanetter B; Sebening H; Hartmann F; Klein G J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S36-40. PubMed ID: 2478790 [TBL] [Abstract][Full Text] [Related]
27. [The acute, chronic continuous after treatment and chronic intermittent with a variable therapeutic window (4 and 6 hours) hemodynamic effects induced with transdermal nitroglycerin in patients with congestive heart failure]. Nodari S; Metra M; Gei P; Danesi R; Furloni R; Cuminetti S; Dei Cas L Cardiologia; 1991 Jun; 36(6):451-60. PubMed ID: 1769029 [TBL] [Abstract][Full Text] [Related]
28. [Hemodynamic and clinical effects and treatment tolerance with low-dose iv amrinone in patients with refractory heart failure: a multicenter study. The Group for Research on Amrinone in the Treatment of Refractory Heart Failure]. Dei Cas L; Metra M; Nodari S; Raddino R; Visioli O Cardiologia; 1991 May; 36(5):363-71. PubMed ID: 1756541 [TBL] [Abstract][Full Text] [Related]
29. Hemodynamic and clinical effects of captopril in patients with severe congestive heart failure. Nigri A; Mangieri E; Martuscelli E; Danesi A; Sardella G; Berni A; Sardella F Cardiologia; 1989 Jun; 34(6):525-9. PubMed ID: 2676169 [TBL] [Abstract][Full Text] [Related]
30. [Acute and long-term effect of captopril in severe chronic heart failure]. Kikis D; Heck I; Stumpe KO; Esser H Dtsch Med Wochenschr; 1985 Apr; 110(15):583-8. PubMed ID: 2983968 [TBL] [Abstract][Full Text] [Related]
31. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854 [TBL] [Abstract][Full Text] [Related]
32. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750 [TBL] [Abstract][Full Text] [Related]
33. [Hemodynamic study on a new antihypertensive drug (a pyridopyridazine) in the treatment of hypertensive crisis and resistent hypertension. First findings in man (author's transl)]. Lehmann HU; Witt E; Hochrein H Z Kardiol; 1977 Apr; 66(4):203-9. PubMed ID: 857459 [TBL] [Abstract][Full Text] [Related]
34. Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Hagemeijer F; Brand HJ; van Mechelen R Am J Cardiol; 1989 Mar; 63(9):571-6. PubMed ID: 2919561 [TBL] [Abstract][Full Text] [Related]
35. [Evaluation of a pyridopyridazine as a drug with marked antihypertensive properties (author's transl)]. Lehmann HU; Witt E; Hochrein H Med Klin; 1977 Jul; 72(28-29):1203-8. PubMed ID: 887046 [TBL] [Abstract][Full Text] [Related]
36. Effect of intravenous pimobendan (UDCG 115 BS) on hemodynamics and left ventricular volumes in idiopathic dilative cardiomyopathy. Permanetter B; Sebening H; Hartmann F; Baumann G; Lutilsky L J Cardiovasc Pharmacol; 1989 Dec; 14(6):803-9. PubMed ID: 2481765 [TBL] [Abstract][Full Text] [Related]
37. Acute hemodynamic effects of endralazine: a new vasodilator for chronic refractory congestive heart failure. Quyyumi AA; Wagstaff D; Evans TR Am J Cardiol; 1983 May; 51(8):1353-7. PubMed ID: 6846162 [TBL] [Abstract][Full Text] [Related]
38. Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients. Kivikko M; Sundberg S; Karlsson MO; Pohjanjousi P; Colucci WS Scand Cardiovasc J; 2011 Apr; 45(2):86-90. PubMed ID: 21133820 [TBL] [Abstract][Full Text] [Related]
39. Intravenous captopril in congestive heart failure. Ahmad S; Giles TD; Roffidal LE; Haney Y; Given MB; Sander GE J Clin Pharmacol; 1990 Jul; 30(7):609-14. PubMed ID: 2202753 [TBL] [Abstract][Full Text] [Related]
40. Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan. Kato K Cardiology; 1997; 88 Suppl 2():28-36. PubMed ID: 9142433 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]